ScreenerHero

ORGS Orgenesis Inc.

NAS · US · Healthcare · Biotechnology · orgenesis.com
0.5900USD-11.85%Mkt Cap: 5.78M $P/E: —

Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.78M USD
Enterprise Value20.49M USD
Revenue (TTM)1.03M USD
Gross Profit-8.47M USD
Net Income (TTM)-48.16M USD
Revenue/Share0.25 USD
Last Price0.5900 USD
Fiscal Year EndDec 2024
MR QuarterSep 2024
Employees77
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)0.90
PEG—
EV/EBITDA-0.86
EV/Revenue19.80
P/S5.21
P/B-0.08
EPS (TTM)-16.59
EPS (Forward)0.61
52W Range
0.004259% of range1.000
52W High1.000 USD
52W Low0.0042 USD
Profitability
Gross Margin-818.55%
Oper. Margin-2196.25%
EBITDA Margin0.00%
Profit Margin-4653.62%
ROE128.44%
ROA-3565.14%
Growth
Revenue Growth215.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.08M USD
CapEx (TTM)263.00K USD
FCF Margin-524.83%
FCF Yield-93.95%
Net Debt17.09M USD
Net Debt/EBITDA-0.71
Balance Sheet
Debt/Equity-0.49
Current Ratio0.03
Quick Ratio0.00
Book Value/Sh-7.25 USD
Cash/Share0.02 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateNov 16, 2017
Splits
Last Split1:10
Split DateSep 25, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.9.80M
Float3.64M
Insiders46.42%
Institutions0.52%
Short Interest
Short Ratio1.2d
Short % Float0.80%
Short % Out.0.71%
Shares Short33.83K
Short (prev mo.)37.74K
Technical
SMA 500.3712 (+58.9%)
SMA 2000.3707 (+59.2%)
Beta2.87
S&P 52W Chg16.45%
Avg Vol (30d)539
Avg Vol (10d)174
Technical Indicators
RSI (14)57.9
MACD0.0612
MACD Signal0.0143
MACD Hist.+0.0469
BB Upper0.7276 USD
BB Middle0.3186 USD
BB Lower-0.0904 USD
BB Width256.72%
ATR (14)0.2025 USD
Vol Ratio (20d)0.14x